Legal & Disputes
Schall, Brown & Schwartz Investigates NeuroPace Over Q3 2026 Revenue Decline and Guidance Cut
By News Desk ·
Key takeaways
- Schall, Brown & Schwartz LLP is investigating NeuroPace for possible securities law violations tied to its Q3 2026 results.
- NeuroPace reported a year-over-year revenue decline and cut its full-year 2026 revenue guidance on November 13, 2026.
- NeuroPace shares fell 37.1% on the day the Q3 2026 results were released.
Schall, Brown & Schwartz LLP is investigating NeuroPace, Inc. for possible violations of the securities laws, the firm said in a Business Wire announcement on November 21, 2026. The investigation concerns whether NeuroPace issued false or misleading statements or failed to disclose information pertinent to investors.
What the SBS Investigation Alleges
The investigation centers on NeuroPace's Q3 2026 financial results, which the company reported on November 13, 2026. NeuroPace disclosed a year-over-year decline in revenues and cut its full-year 2026 revenue guidance, attributing the shortfall in part to "local operational issues." Shares of NeuroPace fell 37.1% on the same day. SBS, a national shareholder rights litigation firm, invited shareholders who suffered a loss to contact Brian Schall or David Schwartz to discuss their rights free of charge. The firm's announcement follows a similar investigation into Advanced Micro Devices that SBS announced on November 20, 2026, citing a Hunterbrook report alleging AMD issued false statements and bills over 20% of revenue to China and Hong Kong; AMD shares fell more than 7.7% that day.
NeuroPace's Core RNS Business
NeuroPace markets the FDA-approved RNS System, a closed-loop brain-responsive neuromodulation device for adults with drug-resistant focal epilepsy, according to akta.pro company records. The Mountain View company was founded in 1997 and serves Level 4 epilepsy centers in the U.S. The same records show NeuroPace raised its full-year 2026 revenue guidance to $99-101 million on a continuing-operations basis, reflecting expected 21-23% underlying growth in its core RNS System business. NeuroPace reported full-year 2025 revenue of $100 million, representing 25% growth compared to 2024.
NeuroPace's Guidance History Before the Cut
NeuroPace's guidance trajectory shifted during 2026. In August 2026, the company reported second-quarter earnings with a narrowed net loss of US$6.20 million and revenue growth of 17% to US$22.8 million, while revising its full-year 2026 revenue guidance upward to between $99.5 million and $101.5 million, according to Simply Wall St. ScanX reported the same month that the raised range exceeded the consensus estimate of $99.913 million. In September 2026, Investing.com reported that NeuroPace's IGE indication faced an open FDA review after a non-approvable letter, and that the NAUTILUS trial missed its primary endpoint but showed 100% median seizure reduction at 24 months.
NeuroPace's Next Steps
NeuroPace has not stated a date for the conclusion of the SBS investigation. The company's IGE indication remains under FDA review following the non-approvable letter, according to Investing.com.